Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. (Q38126945)

From Wikidata

Revision as of 12:33, 10 January 2019 by QuickStatementsBot (talk | contribs) (‎Added qualifier: object named as (P1932): Jens J Holst, #quickstatements; #temporary_batch_1545279845961; invoked by sourcemd_batch_processing on behalf of User:Daniel Mietchen (batch 4717))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 07 August 2013

Language	Label	Description	Also known as
English	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.	scientific article published on 07 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Carolyn F. Deacon

object named as

Carolyn F Deacon

1

0 references

Jens Juul Holst

object named as

Jens J Holst

0 references

publication date

7 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

2047-2058

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Glucagon-like peptide-1, glucose homeostasis and diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

The safety of incretin-based therapies--review of the scientific evidence

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Incretin therapy and islet pathology: a time for caution

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Sitagliptin reduces albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Potential cardiovascular effects of incretin-based therapies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

21 January 2018

Identifiers

10.1517/14656566.2013.824966

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38126945&oldid=831514727"